Fractyl Health, Inc. Common Stock
NASDAQ:GUTSBiotechnology
-$0.01 today
- Market cap
- $55.18M
- Beta
- 2.34
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.42
Volume 0.10M
Average 2.07M
Returns on capital
Fractyl Health, Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1490.3%
avg -264.9%
ROIC
-89.5%
avg -146.9%
ROA
-116.1%
avg -117.8%
Analysis
ROIC is currently the strongest return metric at -89.5% versus its period average of -146.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Harith Rajagopalan | Co-Founder, Chief Executive Officer & Director | USD 976.42K | 49 | 540.56K | 0.75% |
Jay D. Caplan BSEE | Co-Founder, Chief Product Officer & President | USD 666.86K | 64 | — | — |
Sarah S. Toomey | General Counsel & Corporate Secretary | USD 638.65K | 51 | — | — |
Lara Smith Weber | Chief Financial Officer & Treasurer | USD 580.99K | 51 | 20.00K | 0.03% |
Brian Luque | Head of Investor Relations & Corporate Development | — | — | — | — |
Jon Fitzgerald | Senior Vice President of Regulatory, Quality & Clinical | — | — | — | — |
Mike Zumdahl | Senior Vice President of Market Access & Commercial Strategy | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$187,316.02
Sells
0
$0.00
Net Transaction Value
+$187,316.02
Net buying
Most Active
BRADLEY WILLIAM
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 14, 26Sep 14, 2026 | BRADLEY WILLIAM Direct | Buy | $39.9K$39,903.15 |
| Jun 12, 26Jun 12, 2026 | Royan Ajay Direct | Buy | $19.6K$19,596.00 |
| Jun 10, 26Jun 10, 2026 | BRADLEY WILLIAM Direct | Buy | $50.3K$50,328.66 |
| Jun 10, 26Jun 10, 2026 | Sheffield Ian Direct | Buy | $25.5K$25,529.00 |
| Jun 10, 26Jun 10, 2026 | Rajagopalan Harith Direct | Buy | $18.3K$18,252.50 |
| Jun 8, 26Jun 8, 2026 | Smith Weber Lara Direct | Buy | $13.7K$13,708.00 |
| Dec 4, 25Dec 4, 2025 | Rajagopalan Harith Direct | Buy | $20K$19,998.72 |
Summary
Insiders reported 7 buys worth $187,316.02 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $187,316.02. BRADLEY WILLIAM was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Fractyl Health, Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about GUTS's management, answered from reported figures.
Who manages GUTS?
Fractyl Health, Inc. Common Stock (GUTS) lists 7 active executives. The top listed executive is Harith Rajagopalan, Co-Founder, Chief Executive Officer & Director.
Are GUTS insiders buying or selling?
Recent insider activity shows net buying of $60.20M.
Continue the stock analysis
Jump to another research area for this company.